Market Cap 7.76M
Revenue (ttm) 0.00
Net Income (ttm) -7.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 46,700
Avg Vol 376,320
Day's Range N/A - N/A
Shares Out 12.85M
Stochastic %K 24%
Beta 0.64
Analysts Sell
Price Target $34.00

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 933 3121
Fax: 972 3 509 7196
Address:
4 Oppenheimer Street, Science Park, Rehovot, Israel
Winorbust
Winorbust Feb. 4 at 4:52 PM
$PPBT @Purplepayday I literally said the same thing to @YamiDawg about how laughably small our sample sizes are, which is why our data isn’t as mind blowing as many in here have said including Smitty. PPBT is nearly broke, no big partners, price too low to dilute enough to succeed. So at this point they are just milking retail to keep lights on and their pockets filled with cash. Period.
0 · Reply
Purplepayday
Purplepayday Feb. 4 at 4:07 PM
$PPBT The share price as of February 3, 2026 is 0.59 / share. Previously, on February 4, 2025, the share price was 3.19 / share. This represents a decline of 81.53% over that period. 👍
0 · Reply
Purplepayday
Purplepayday Feb. 4 at 3:25 PM
$PPBT Purple Biotech has noted that larger sample sizes are necessary to fully confirm some of these findings.
0 · Reply
Smittysixty
Smittysixty Feb. 4 at 2:56 PM
$PPBT Today’s World Cancer Day post actually lines up perfectly with where cutting‑edge oncology is headed. “United by Unique” is basically the core theme of modern cancer research: • Precision medicine • Targeting specific resistance pathways • Fixing the tumor microenvironment • Personalized immune activation And that’s exactly what PB’s pipeline is built for: • NT‑219 → hits STAT3 + IRS1/2 to overcome PD‑1 resistance • CM24 → targets CEACAM1 to reduce immune suppression • IM1240 → engineered for controlled T‑cell + NK‑cell activation The industry is moving toward individualized, mechanism‑driven therapies — and PB is already operating in that lane. Their post wasn’t just feel‑good messaging… it quietly reinforces the precision‑oncology strategy behind the entire pipeline.
1 · Reply
Purplepayday
Purplepayday Feb. 4 at 2:44 PM
$PPBT 👀 Looks like short’s want to cover at $0.566 early today 🤔🤷🏻‍♂️
0 · Reply
ImadogImaMut
ImadogImaMut Feb. 4 at 2:27 PM
$PPBT Just checking back I’ve swung so many names since I left my Ppbt fully a few weeks ago 🤧🙂‍↕️l😆 But in a snakes and ladders market I’ve been in goog, Amazon , Salesfore omg , stopped out ( many others . I’ve lost a little 😆but I feel like I’m positioned well : Here is all I have for trading is MDA, MDAF in US, a space satellite co and SCYX a small biotech with an FDA approved product for new onset / Moderate to severe Vaginal yeast infections ( with a GSK partnership ) and lots of cash in the bank 🏦 there should be a vaginal emoji no? So that’s all , but I am down a few k but for the amt of fun and improvement in decision making it has been worth the effort and money 🫡 Women would you chime in what these yeast infections are extremely upsetting to women and well that is my investment activity ❤️
1 · Reply
allgoodstill
allgoodstill Feb. 4 at 2:20 PM
$PPBT Genuinely curious!!! Someone educate me please. Is there a more scammy Israeli bio than this POS?
1 · Reply
Purplepayday
Purplepayday Feb. 4 at 11:48 AM
$PPBT $0.5380 is the point where delisting starts here…… Unless, of course they dilute before we reach that share price 🧐 Either with lowering the exercise price of the $1 warrants or exercise their $0.60 shares…. Or, just simple dilute shareholders even more 🤷🏻‍♂️
1 · Reply
WallStWireAds
WallStWireAds Feb. 4 at 7:11 AM
$PPBT $JANX $XLO $BLRX >> After BMS’s $850M Bet on Tumor-Activated Immunotherapy, Investors Are Asking: Who’s Next? https://www.bioreview.com/after-bmss-850m-bet-on-tumor-activated-immunotherapy-investors-are-asking-whos-next/
2 · Reply
Stocktelligence
Stocktelligence Feb. 3 at 9:12 PM
$PPBT this feels like purple
2 · Reply
Latest News on PPBT
Purple Biotech Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 6 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results


Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025, 7:10 AM EDT - 9 months ago

Purple Biotech Reports First Quarter 2025 Financial Results


Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025, 7:30 AM EDT - 9 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer


Why Is Purple Biotech Stock Trading Higher On Monday?

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?


Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results


Purple Biotech Reports First Quarter 2024 Financial Results

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results


Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219


Purple Biotech Reports Third Quarter 2023 Financial Results

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results


Purple Biotech Announces $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering


Purple Biotech Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results


Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Mar 24, 2023, 7:00 AM EDT - 3 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron


Winorbust
Winorbust Feb. 4 at 4:52 PM
$PPBT @Purplepayday I literally said the same thing to @YamiDawg about how laughably small our sample sizes are, which is why our data isn’t as mind blowing as many in here have said including Smitty. PPBT is nearly broke, no big partners, price too low to dilute enough to succeed. So at this point they are just milking retail to keep lights on and their pockets filled with cash. Period.
0 · Reply
Purplepayday
Purplepayday Feb. 4 at 4:07 PM
$PPBT The share price as of February 3, 2026 is 0.59 / share. Previously, on February 4, 2025, the share price was 3.19 / share. This represents a decline of 81.53% over that period. 👍
0 · Reply
Purplepayday
Purplepayday Feb. 4 at 3:25 PM
$PPBT Purple Biotech has noted that larger sample sizes are necessary to fully confirm some of these findings.
0 · Reply
Smittysixty
Smittysixty Feb. 4 at 2:56 PM
$PPBT Today’s World Cancer Day post actually lines up perfectly with where cutting‑edge oncology is headed. “United by Unique” is basically the core theme of modern cancer research: • Precision medicine • Targeting specific resistance pathways • Fixing the tumor microenvironment • Personalized immune activation And that’s exactly what PB’s pipeline is built for: • NT‑219 → hits STAT3 + IRS1/2 to overcome PD‑1 resistance • CM24 → targets CEACAM1 to reduce immune suppression • IM1240 → engineered for controlled T‑cell + NK‑cell activation The industry is moving toward individualized, mechanism‑driven therapies — and PB is already operating in that lane. Their post wasn’t just feel‑good messaging… it quietly reinforces the precision‑oncology strategy behind the entire pipeline.
1 · Reply
Purplepayday
Purplepayday Feb. 4 at 2:44 PM
$PPBT 👀 Looks like short’s want to cover at $0.566 early today 🤔🤷🏻‍♂️
0 · Reply
ImadogImaMut
ImadogImaMut Feb. 4 at 2:27 PM
$PPBT Just checking back I’ve swung so many names since I left my Ppbt fully a few weeks ago 🤧🙂‍↕️l😆 But in a snakes and ladders market I’ve been in goog, Amazon , Salesfore omg , stopped out ( many others . I’ve lost a little 😆but I feel like I’m positioned well : Here is all I have for trading is MDA, MDAF in US, a space satellite co and SCYX a small biotech with an FDA approved product for new onset / Moderate to severe Vaginal yeast infections ( with a GSK partnership ) and lots of cash in the bank 🏦 there should be a vaginal emoji no? So that’s all , but I am down a few k but for the amt of fun and improvement in decision making it has been worth the effort and money 🫡 Women would you chime in what these yeast infections are extremely upsetting to women and well that is my investment activity ❤️
1 · Reply
allgoodstill
allgoodstill Feb. 4 at 2:20 PM
$PPBT Genuinely curious!!! Someone educate me please. Is there a more scammy Israeli bio than this POS?
1 · Reply
Purplepayday
Purplepayday Feb. 4 at 11:48 AM
$PPBT $0.5380 is the point where delisting starts here…… Unless, of course they dilute before we reach that share price 🧐 Either with lowering the exercise price of the $1 warrants or exercise their $0.60 shares…. Or, just simple dilute shareholders even more 🤷🏻‍♂️
1 · Reply
WallStWireAds
WallStWireAds Feb. 4 at 7:11 AM
$PPBT $JANX $XLO $BLRX >> After BMS’s $850M Bet on Tumor-Activated Immunotherapy, Investors Are Asking: Who’s Next? https://www.bioreview.com/after-bmss-850m-bet-on-tumor-activated-immunotherapy-investors-are-asking-whos-next/
2 · Reply
Stocktelligence
Stocktelligence Feb. 3 at 9:12 PM
$PPBT this feels like purple
2 · Reply
Demon7
Demon7 Feb. 3 at 8:21 PM
$PPBT Got my loss statement today from this stock. Did anything change ?
2 · Reply
Purplepayday
Purplepayday Feb. 3 at 7:47 PM
$PPBT Maybe this is just Fact and not FUD 🤔 We have always had a high percentage Dark Pool trading here Smitty…. And share price have always been declining, so i’m more leaning to this: High-percentage Dark Pool trading can consist of or include significant short-selling activity. Institutional investors and market makers often use these private, off-exchange venues to execute large, bearish positions without immediately causing price drops in public markets.
1 · Reply
Smittysixty
Smittysixty Feb. 3 at 7:19 PM
$PPBT 👀 ⬇️ Who's accumulating? Maybe the volume in Q4 was a distraction. I think we're seeing quiet accumulation RIGHT NOW. https://chartexchange.com/symbol/nasdaq-ppbt/exchange-volume/
0 · Reply
Smittysixty
Smittysixty Feb. 3 at 7:15 PM
$PPBT Another 70% darkpool volume day. The facts are hard to deny. "What 70% Dark Pool Volume Usually Means 1. Institutions Are Accumulating Quietly When dark pool percentage jumps well above a stock's baseline, it often reflects: • Funds building a position without moving the price • Market makers filling institutional orders internally • Accumulation ahead of a catalyst"
0 · Reply
Winorbust
Winorbust Feb. 3 at 6:49 PM
$PPBT I have to reshare this one because this just made me laugh so hard. @Purplepayday A whopping $210 position Hahaha and they are also losing on the position as well. Is this the tute that Smitty is hyping up?
0 · Reply
demo1one
demo1one Feb. 3 at 4:13 PM
$PPBT buy more goyim
0 · Reply
Purplepayday
Purplepayday Feb. 3 at 1:19 PM
$PPBT Smitty was right 🙏✅ Institutions is loading up with 1500% WOW 🚀
1 · Reply
nebleros
nebleros Feb. 2 at 9:34 PM
$PPBT Would it not be great BP following Smitty's lead..
1 · Reply
Smittysixty
Smittysixty Feb. 2 at 9:27 PM
$PPBT The Non‑Pipeline Signals Are Just as Loud Beyond the science, $PPBT has a stack of classic pre‑M&A signals lining up: • Cash runway forces a decision point — partner, raise, or sell • Management bought shares at these levels, aligning them with a takeout outcome • Investigator‑funded Phase 2 reduces burn and provides independent validation • Strategic silence around late‑cohort NT‑219 data • Three assets at three different value‑inflection stages • Institutional holders already positioned These are the same operational signals that tend to show up right before a company enters a transaction window.
0 · Reply
Winorbust
Winorbust Feb. 2 at 9:08 PM
$PPBT our exec looks like someone who wants to rob shareholders. No wonder he has been arrested before.
1 · Reply
Smittysixty
Smittysixty Feb. 2 at 8:55 PM
$PPBT IM1240: IND‑Ready & Perfectly Timed IM1240 is sitting at the exact stage where early acquisitions happen: • IND‑ready • Clean toxicology • GMP manufacturing complete • Next‑gen T‑cell + NK‑cell activation design Why this is a buyer magnet: Pharma is scooping up IND‑ready immunotherapy platforms before Phase 1 costs hit. It’s cheaper, faster, and gives them full control over development. IM1240 is literally at the front door of Phase 1 — the sweet spot for early‑stage platform M&A.
0 · Reply
Smittysixty
Smittysixty Feb. 2 at 8:54 PM
$PPBT CM24: Randomized Survival Data in Hand CM24 already hit a major de‑risking milestone: • Completed randomized Phase 2 survival study • Targets CEACAM1 — a hot immunotherapy resistance pathway • Combo‑ready with PD‑1 Why this is M&A territory: Randomized survival data is where pharma evaluates: • combo potential • label expansion • whether to take it into Phase 3 (which they usually fund) PB can’t run a Phase 2b or 3 alone — which makes CM24 a prime candidate for a partner or buyer who wants a late‑stage immunotherapy asset.
0 · Reply